Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
IPI-9119
Cat. No.:
OB0225LY-0011
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
IPI-9119 is a selective and irreversible inhibitor of fatty acid synthase (FASN). It selectively inhibits the thioesterase domain of FASN by promoting acylation of the catalytic serine, thereby blocking lipid synthesis.
Synonym:
1346564-56-4; 4-[[4-(2,6-Difluorophenyl)-5-oxotetrazole-1-carbonyl]-propan-2-ylamino]-3-phenoxybenzoic acid
CAS No.:
1346564-56-4
Compound CID:
68208572
Formula:
C24H19F2N5O5
Formula Weight:
495.43
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
IPI-9119 can be used to study the effects of FASN inhibition on lipid metabolism and tumor growth in castration-resistant prostate cancer models.
Library Information
Targets:
Fatty acid synthesis
Receptors:
Fatty acid synthase
Pathways:
Metabolism
Plate Number:
AOCL-1
Plate Location:
b2
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
95 mg/mL; 191.75 mM
